바이오시밀러 인슐린 시장 : 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Biosimilar Insulin Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

US $ 4,995 ￦ 6,876,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,043,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,695,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 세계 바이오시밀러 인슐린 시장에 대한 종합적인 분석을 통해 시장 역학, 주요 동인 및 과제, 새로운 동향을 조사했습니다. 이 보고서는 2024년부터 2031년까지의 예측 시장 궤적에 대한 상세한 개요를 제공하며, 바이오시밀러 인슐린 산업의 이해관계자와 의사 결정권자에게 중요한 통찰력을 제공합니다.

세계 바이오시밀러 인슐린 시장 매출 추정치는 2024년 말 기준 19억 달러에 달할 것으로 예상되며, 세계 시장 CAGR은 14.9%로 급증하여 2031년 말에는 50억 달러에 달할 것으로 추정됩니다.

주요 인사이트

• 추정 시장 가치(2024년) : 19억 달러
• 예상 시장 가치(2031년) : 50억 달러
• 세계 시장 성장률(2024-2031년 CAGR) : 14.9%.

바이오시밀러 인슐린 시장 - 조사 범위 :

세계 당뇨병 유병률 증가는 바이오시밀러 인슐린 수요를 견인하는 주요 요인 중 하나입니다. 인슐린 치료가 필요한 환자가 증가하고 있으며, 바이오시밀러는 브랜드 인슐린 제제에 대한 비용 효율적인 대안을 제공합니다. 특히 인슐린에 대한 접근성이 제한적인 지역에서 정부와 의료 서비스 제공업체들은 의료비 절감을 위해 바이오시밀러의 도입을 추진하고 있습니다. 이러한 추세는 바이오시밀러 제품의 승인 및 판매를 우대하는 규제 정책으로 뒷받침되고 있습니다.

시장 성장의 촉진요인:

바이오시밀러 인슐린 시장 성장의 주요 동인은 당뇨병, 특히 제 2형 당뇨병의 유병률 증가와 보다 저렴한 인슐린 제제에 대한 수요 증가를 꼽을 수 있습니다. 브랜드 인슐린의 가격 상승으로 인해 보다 저렴한 대체품에 대한 수요가 증가하면서 바이오시밀러 인슐린은 환자와 의료 시스템에 매력적인 대안으로 떠오르고 있습니다. 또한, 바이오시밀러의 승인과 시장 진입을 촉진하기 위한 규제 프레임워크가 진화하고 있어 시장 성장을 더욱 촉진하고 있습니다.

시장 성장 억제요인 :

바이오시밀러 인슐린 시장은 그 잠재력에도 불구하고 몇 가지 문제에 직면해 있습니다. 가장 큰 우려 중 하나는 의료진이 기존 브랜드 인슐린 제제에서 바이오시밀러 제제로 전환하는 것을 꺼려한다는 점입니다. 이러한 주저는 종종 바이오시밀러의 효능과 안전성이 오리지널 의약품에 비해 불확실하기 때문인 경우가 많습니다. 또한, 바이오시밀러 인슐린의 약사 승인 절차가 복잡하고 비용이 많이 들어 시장 진입 장벽으로 작용하고 있습니다. 지적재산권 문제와 특허 소송도 시장 확대의 위험요소로 작용합니다.

시장 기회 :

바이오시밀러 인슐린 시장은 성장과 확장의 큰 기회가 있습니다. 인슐린 제제의 특허가 만료되면 바이오시밀러 제제가 시장에 진입하여 경쟁이 치열해져 가격이 하락할 수 있습니다. 또한, 제약회사와 의료 서비스 제공업체간의 제휴는 바이오시밀러의 보급을 촉진할 수 있습니다. 개인 맞춤형 의료와 환자 중심 의료에 대한 관심이 높아지면서 바이오시밀러 인슐린을 유연하고 저렴한 치료 옵션으로 보급할 수 있는 기회가 될 수 있습니다. 또한, 바이오시밀러의 장점에 대한 인식과 교육이 개선되면 의료진과 환자의 거부감을 극복하는 데 도움이 될 수 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위/분류
• 시장의 정의/범위/제한
• 포함과 제외

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 제품 혁신/개발 동향

제4장 중요 성공 요인

• 주요 제품 USP/기능 분석
• 규제 시나리오
• 제조업체 주요 프로모션 전략
• 최근 제품 릴리스
• 밸류체인 분석
• 지역별 제품 채택 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• 2023년 시장 시나리오
• COVID-19와 영향 분석
  • 제품별
  • 유통 채널별
  • 지역별

제7장 세계의 바이오시밀러 인슐린 시장 수요 분석(금액)

• 과거 시장(금액) 분석, 2019-2023년
• 현재 및 향후 시장(금액) 예측, 2024-2031년

제8장 세계의 바이오시밀러 인슐린 시장 - 가격 분석

• 제품별 지역별 가격 분석
• 세계 평균 가격 분석 벤치마크
• 가격 분석
  • 제조업체 레벨 가격 결정
  • 유통업체 레벨 가격 결정
• 가격 결정의 전제조건

제9장 세계의 바이오시밀러 인슐린 시장 분석, 제품별

• 서론/주요 조사 결과
• 과거 시장 규모(금액) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액) 분석과 예측, 제품별, 2024-2031년
  • Insulin Glargine
  • Insulin Analog
  • 기타
• 제품별 시장의 매력 분석

제10장 세계의 바이오시밀러 인슐린 시장 분석, 유통 채널별

• 서론/주요 조사 결과
• 과거 시장 규모(금액) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액) 분석과 예측, 제품별, 2024-2031년
  • 병원 약국
  • 소매 약국
  • 온라인 약국
• 유통 채널별 시장의 매력 분석

제11장 세계의 바이오시밀러 인슐린 시장 분석, 지역별

• 서론
• 과거 시장 규모(금액) 분석, 2019-2023년
• 현재 및 향후 시장 규모(금액) 분석과 예측, 제품별, 2024-2031년
  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양(APAC)
  • 중동 및 아프리카(MEA)
• 지역별 시장의 매력 분석

제12장 북미의 바이오시밀러 인슐린 시장 분석

제13장 라틴아메리카의 바이오시밀러 인슐린 시장 분석

제14장 유럽의 바이오시밀러 인슐린 시장 분석

제15장 아시아태평양(APAC)의 바이오시밀러 인슐린 시장 분석

제16장 중동 및 아프리카(MEA)의 바이오시밀러 인슐린 시장 분석

제17장 시장 구조 분석

• 기업 Tier별 시장 분석
• 주요 기업의 시장 점유율 분석
• 시장 입지 분석

제18장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마킹
• 경쟁 상세
  • Biocon
  • Eli Lilly and Company
  • Sanofi
  • BGP Pharma
  • Aspen
  • Mylan(Viatris)

제19장 사용된 전제조건과 두자어

제20장 조사 방법

LSH

영문 목차

영문목차

Persistence Market Research presents a comprehensive analysis of the global Biosimilar Insulin Market, examining the market dynamics, key drivers, challenges, and emerging trends. This report offers a detailed overview of the projected market trajectory from 2024 through 2031, providing critical insights for stakeholders and decision-makers in the biosimilar insulin industry.

Revenue from the global biosimilar insulin market reached US$ 1.9 Bn at the end of 2024, with the global market estimated to surge ahead at a value CAGR of 14.9% to reach US$ 5 Bn by the end of 2031.

Key Insights:

• Estimated Market Value (2024): USD 1.9 Billion
• Projected Market Value (2031): USD 5 Billion
• Global Market Growth Rate (CAGR 2024 to 2031): 14.9%

Biosimilar Insulin Market - Report Scope:

The growing prevalence of diabetes globally is one of the primary factors driving the demand for biosimilar insulin. An increasing number of patients require insulin therapy, and biosimilars offer a cost-effective alternative to branded insulin products. Governments and healthcare providers are promoting biosimilar adoption to reduce healthcare expenditure, especially in regions with limited access to insulin. This trend is further supported by regulatory policies favoring the approval and marketing of biosimilar products.

Market Growth Drivers:

The key drivers of growth in the biosimilar insulin market include the increasing prevalence of diabetes, especially type 2 diabetes, and the growing demand for more affordable insulin options. The rising cost of branded insulin has created a need for cheaper alternatives, making biosimilar insulin an attractive choice for patients and healthcare systems. Additionally, regulatory frameworks are evolving to facilitate the approval and market entry of biosimilars, further boosting market growth.

Market Restraints:

Despite its potential, the biosimilar insulin market faces several challenges. One of the primary concerns is the reluctance among healthcare professionals to switch from established branded insulin products to biosimilars. This hesitancy is often due to uncertainty about the efficacy and safety of biosimilars compared to their branded counterparts. Furthermore, the regulatory approval process for biosimilar insulin can be complex and costly, creating barriers for market entry. Intellectual property issues and patent litigation also pose risks to market expansion.

Market Opportunities:

The biosimilar insulin market offers significant opportunities for growth and expansion. As more insulin patents expire, new biosimilar products can enter the market, increasing competition and driving down prices. Additionally, partnerships between pharmaceutical companies and healthcare providers can facilitate wider adoption of biosimilars. The growing focus on personalized medicine and patient-centric care provides an opportunity to promote biosimilar insulin as a flexible and affordable treatment option. Furthermore, increased awareness and education about the benefits of biosimilars can help overcome resistance among healthcare professionals and patients.

Key Questions Addressed in the Report:

• What is the Expected Value CAGR of the Biosimilar Insulin Market from 2024 to 2031?
• What are the Primary Drivers for the Growth of the Biosimilar Insulin Market?
• Which Regions Offer the Most Significant Growth Opportunities for the Biosimilar Insulin Market?
• Who are the Key Players in the Global Biosimilar Insulin Market?
• What are the Major Challenges Faced by the Biosimilar Insulin Market?

Competitive Landscape and Business Strategies:

Leading players in the biosimilar insulin market include Mylan N.V., Biocon Limited, Sanofi, and Eli Lilly and Company. These companies focus on product innovation, strategic partnerships, and market expansion to maintain a competitive edge. Strategies include expanding manufacturing capabilities, investing in R&D for new biosimilar products, and entering strategic alliances with other pharmaceutical companies to broaden market reach. Additionally, collaborations with healthcare providers and insurance companies help drive biosimilar adoption and increase market penetration.

Key Companies Profiled:

• Biocon
• Eli Lilly and Company
• Sanofi
• BGP Pharma
• Aspen
• Mylan (Viatris)

Biosimilar Insulin Market Segmentation:

Biosimilar Insulin Market by Product:

• Insulin Glargine
• Insulin Analog
• Others

Biosimilar Insulin Market by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Biosimilar Insulin Market by Region:

• North America Biosimilar Insulin Market
• Latin America Biosimilar Insulin Market
• Europe Biosimilar Insulin Market
• APAC Biosimilar Insulin Market
• Middle East & Africa Biosimilar Insulin Market

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusion And Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Key Products USP/Feature Analysis
• 4.2. Regulatory Scenario
• 4.3. Key Promotional Strategies By Manufacturers
• 4.4. Recent Product Launches
• 4.5. Value Chain Analysis
• 4.6. Product Adoption Analysis by Region

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Industry Outlook
  • 5.1.3. Parent Market Analysis (Insulin Market)
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Growing Prevalence Of Diabetes
  • 5.2.2. Increasing Research and Development Activities
  • 5.2.3. New Product Launches
  • 5.2.4. Increasing Number Of Clinical Trials
  • 5.2.5. Patent Expiry for Insulin
  • 5.2.6. Growing Geriatric Population
  • 5.2.7. Increasing Insulin Manufacturers
  • 5.2.8. Requirement of Cost-Efficient Products
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. 2023 Market Scenario
• 6.2. COVID-19 and Impact Analysis
  • 6.2.1. By Product
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Region

7. Global Biosimilar Insulin Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Biosimilar Insulin Market - Pricing Analysis

• 8.1. Regional Pricing Analysis By Product
• 8.2. Global Average Pricing Analysis Benchmark
• 8.3. Pricing Break-up
  • 8.3.1. Manufacturer Level Pricing
  • 8.3.2. Distributor Level Pricing
• 8.4. Pricing Assumptions

9. Global Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031, By Product

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Product, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2024-2031
  • 9.3.1. Insulin Glargine
  • 9.3.2. Insulin Analog
  • 9.3.3. Others
• 9.4. Market Attractiveness Analysis By Product

10. Global Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2031
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031, By Region

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. Asia Pacific (APAC)
  • 11.3.5. Middle East and Africa (MEA)
• 11.4. Market Attractiveness Analysis By Region

12. North America Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

• 12.1. Introduction
• 12.2. Pricing Analysis
• 12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 12.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 12.4.1. By Country
    • 12.4.1.1. U.S.
    • 12.4.1.2. Canada
  • 12.4.2. By Product
  • 12.4.3. By Distribution Channel
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Country
  • 12.5.2. By Product
  • 12.5.3. By Distribution Channel
• 12.6. Key Market Participants - Intensity Mapping
• 12.7. Drivers and Restraints - Impact Analysis
• 12.8. Country Level Analysis & Forecast
  • 12.8.1. U.S. Biosimilar Insulin Market
    • 12.8.1.1. Introduction
    • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.1.2.1. By Product
      • 12.8.1.2.2. By Distribution Channel
  • 12.8.2. Canada Biosimilar Insulin Market
    • 12.8.2.1. Introduction
    • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.2.2.1. By Product
      • 12.8.2.2.2. By Distribution Channel

13. Latin America Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

• 13.1. Introduction
• 13.2. Pricing Analysis
• 13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 13.4.1. By Country
    • 13.4.1.1. Brazil
    • 13.4.1.2. Argentina
    • 13.4.1.3. Mexico
    • 13.4.1.4. Rest of Latin America
  • 13.4.2. By Product
  • 13.4.3. By Distribution Channel
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Country
  • 13.5.2. By Product
  • 13.5.3. By Distribution Channel
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. Brazil Biosimilar Insulin Market
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Product
      • 13.8.1.2.2. By Distribution Channel
  • 13.8.2. Argentina Biosimilar Insulin Market
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Product
      • 13.8.2.2.2. By Distribution Channel
  • 13.8.3. Mexico Biosimilar Insulin Market
    • 13.8.3.1. Introduction
    • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.3.2.1. By Product
      • 13.8.3.2.2. By Distribution Channel

14. Europe Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

• 14.1. Introduction
• 14.2. Pricing Analysis
• 14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 14.4.1. By Country
    • 14.4.1.1. Germany
    • 14.4.1.2. Italy
    • 14.4.1.3. France
    • 14.4.1.4. U.K.
    • 14.4.1.5. Spain
    • 14.4.1.6. BENELUX
    • 14.4.1.7. Nordic Countries
    • 14.4.1.8. Russia
    • 14.4.1.9. Rest of Europe
  • 14.4.2. By Product
  • 14.4.3. By Distribution Channel
• 14.5. Market Attractiveness Analysis
  • 14.5.1. By Country
  • 14.5.2. By Product
  • 14.5.3. By Distribution Channel
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Germany Biosimilar Insulin Market
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Product
      • 14.8.1.2.2. By Distribution Channel
  • 14.8.2. France Biosimilar Insulin Market
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Product
      • 14.8.2.2.2. By Distribution Channel
  • 14.8.3. Italy Biosimilar Insulin Market
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Product
      • 14.8.3.2.2. By Distribution Channel
  • 14.8.4. Spain Biosimilar Insulin Market
    • 14.8.4.1. Introduction
    • 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.4.2.1. By Product
      • 14.8.4.2.2. By Distribution Channel
  • 14.8.5. U.K. Biosimilar Insulin Market
    • 14.8.5.1. Introduction
    • 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.5.2.1. By Product
      • 14.8.5.2.2. By Distribution Channel
  • 14.8.6. BENULUX Biosimilar Insulin Market
    • 14.8.6.1. Introduction
    • 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.6.2.1. By Product
      • 14.8.6.2.2. By Distribution Channel
  • 14.8.7. Nordic Countries Biosimilar Insulin Market
    • 14.8.7.1. Introduction
    • 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.7.2.1. By Product
      • 14.8.7.2.2. By Distribution Channel
  • 14.8.8. Russia Biosimilar Insulin Market
    • 14.8.8.1. Introduction
    • 14.8.8.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.8.2.1. By Product
      • 14.8.8.2.2. By Distribution Channel

15. Asia Pacific (APAC) Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

• 15.1. Introduction
• 15.2. Pricing Analysis
• 15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 15.4.1. By Country
    • 15.4.1.1. China
    • 15.4.1.2. Japan
    • 15.4.1.3. India
    • 15.4.1.4. Australia
    • 15.4.1.5. New Zealand
  • 15.4.2. By Product
  • 15.4.3. By Distribution Channel
• 15.5. Market Attractiveness Analysis
  • 15.5.1. By Country
  • 15.5.2. By Product
  • 15.5.3. By Distribution Channel
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. China Biosimilar Insulin Market
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Product
      • 15.8.1.2.2. By Distribution Channel
  • 15.8.2. Japan Biosimilar Insulin Market
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Product
      • 15.8.2.2.2. By Distribution Channel
  • 15.8.3. India Biosimilar Insulin Market
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Product
      • 15.8.3.2.2. By Distribution Channel
  • 15.8.4. Australia Biosimilar Insulin Market
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Product
      • 15.8.4.2.2. By Distribution Channel
  • 15.8.5. New Zealand Biosimilar Insulin Market
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Product
      • 15.8.5.2.2. By Distribution Channel

16. Middle East and Africa (MEA) Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

• 16.1. Introduction
• 16.2. Pricing Analysis
• 16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 16.4.1. By Country
    • 16.4.1.1. GCC Countries
    • 16.4.1.2. Israel
    • 16.4.1.3. Turkey
    • 16.4.1.4. Egypt
    • 16.4.1.5. North Africa
    • 16.4.1.6. South Africa
    • 16.4.1.7. Rest of Middle East and Africa
  • 16.4.2. By Product
  • 16.4.3. By Distribution Channel
• 16.5. Market Attractiveness Analysis
  • 16.5.1. By Country
  • 16.5.2. By Product
  • 16.5.3. By Distribution Channel
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. GCC Countries Biosimilar Insulin Market
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Product
      • 16.8.1.2.2. By Distribution Channel
  • 16.8.2. Israel Biosimilar Insulin Market
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Product
      • 16.8.2.2.2. By Distribution Channel
  • 16.8.3. Turkey Biosimilar Insulin Market
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Product
      • 16.8.3.2.2. By Distribution Channel
  • 16.8.4. Egypt Biosimilar Insulin Market
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.4.2.1. By Product
      • 16.8.4.2.2. By Distribution Channel
  • 16.8.5. North Africa Biosimilar Insulin Market
    • 16.8.5.1. Introduction
    • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.5.2.1. By Product
      • 16.8.5.2.2. By Distribution Channel
  • 16.8.6. South Africa Biosimilar Insulin Market
    • 16.8.6.1. Introduction
    • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.6.2.1. By Product
      • 16.8.6.2.2. By Distribution Channel

17. Market Structure Analysis

• 17.1. Market Analysis by Tier of Companies
• 17.2. Market Share Analysis of Top Players
• 17.3. Market Presence Analysis
  • 17.3.1. Regional footprint of Players
  • 17.3.2. Platform Type foot print by Players
  • 17.3.3. Channel Foot Print by Players

18. Competition Analysis

• 18.1. Competition Dashboard
• 18.2. Competition Benchmarking
• 18.3. Competition Deep Dive
  • 18.3.1. Biocon
    • 18.3.1.1. Overview
    • 18.3.1.2. Product Portfolio
    • 18.3.1.3. Key Financials
    • 18.3.1.4. Geographical Footprint
    • 18.3.1.5. SWOT Analysis
    • 18.3.1.6. Key Developments
    • 18.3.1.7. Strategy Overview
      • 18.3.1.7.1. Channel Strategy
      • 18.3.1.7.2. Marketing Strategy
      • 18.3.1.7.3. Product Strategy
  • 18.3.2. Eli Lilly and Company
    • 18.3.2.1. Overview
    • 18.3.2.2. Product Portfolio
    • 18.3.2.3. Key Financials
    • 18.3.2.4. Geographical Footprint
    • 18.3.2.5. SWOT Analysis
    • 18.3.2.6. Key Developments
    • 18.3.2.7. Strategy Overview
      • 18.3.2.7.1. Channel Strategy
      • 18.3.2.7.2. Marketing Strategy
      • 18.3.2.7.3. Product Strategy
  • 18.3.3. Sanofi
    • 18.3.3.1. Overview
    • 18.3.3.2. Product Portfolio
    • 18.3.3.3. Key Financials
    • 18.3.3.4. Geographical Footprint
    • 18.3.3.5. SWOT Analysis
    • 18.3.3.6. Key Developments
    • 18.3.3.7. Strategy Overview
      • 18.3.3.7.1. Channel Strategy
      • 18.3.3.7.2. Marketing Strategy
      • 18.3.3.7.3. Product Strategy
  • 18.3.4. BGP Pharma
    • 18.3.4.1. Overview
    • 18.3.4.2. Product Portfolio
    • 18.3.4.3. Key Financials
    • 18.3.4.4. Geographical Footprint
    • 18.3.4.5. SWOT Analysis
    • 18.3.4.6. Key Developments
    • 18.3.4.7. Strategy Overview
      • 18.3.4.7.1. Channel Strategy
      • 18.3.4.7.2. Marketing Strategy
      • 18.3.4.7.3. Product Strategy
  • 18.3.5. Aspen
    • 18.3.5.1. Overview
    • 18.3.5.2. Product Portfolio
    • 18.3.5.3. Key Financials
    • 18.3.5.4. Geographical Footprint
    • 18.3.5.5. SWOT Analysis
    • 18.3.5.6. Key Developments
    • 18.3.5.7. Strategy Overview
      • 18.3.5.7.1. Channel Strategy
      • 18.3.5.7.2. Marketing Strategy
      • 18.3.5.7.3. Product Strategy
  • 18.3.6. Mylan (Viatris)
    • 18.3.6.1. Overview
    • 18.3.6.2. Product Portfolio
    • 18.3.6.3. Key Financials
    • 18.3.6.4. Geographical Footprint
    • 18.3.6.5. SWOT Analysis
    • 18.3.6.6. Key Developments
    • 18.3.6.7. Strategy Overview
      • 18.3.6.7.1. Channel Strategy
      • 18.3.6.7.2. Marketing Strategy
      • 18.3.6.7.3. Product Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

관련자료